TY - JOUR
T1 - EGFR mutations in lung cancer
T2 - From tissue testing to liquid biopsy
AU - Fenizia, Francesca
AU - De Luca, Antonella
AU - Pasquale, Raffaella
AU - Sacco, Alessandra
AU - Forgione, Laura
AU - Lambiase, Matilde
AU - Iannaccone, Alessia
AU - Chicchinelli, Nicoletta
AU - Franco, Renato
AU - Rossi, Antonio
AU - Morabito, Alessandro
AU - Rocco, Gaetano
AU - Piccirillo, Maria Carmela
AU - Normanno, Nicola
PY - 2015/6/1
Y1 - 2015/6/1
N2 - The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.
AB - The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.
KW - EGFR mutations
KW - EGFR-TKIs
KW - liquid biopsy
KW - mechanisms of resistance
KW - non-small-cell lung carcinoma
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84930607424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930607424&partnerID=8YFLogxK
U2 - 10.2217/fon.15.23
DO - 10.2217/fon.15.23
M3 - Article
C2 - 26043215
AN - SCOPUS:84930607424
VL - 11
SP - 1611
EP - 1623
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 11
ER -